Lundbeck names new president and CEO
The Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Deborah Dunsire will take up her new position on 1 September 2018.
Trained as a medical doctor, Deborah Dunsire (56) brings more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS, thus bridging a breadth of scientific and business experience. Her professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc.
"It is a great pleasure to announce that Deborah Dunsire will join Lundbeck as President and CEO," says Lars Rasmussen, Chairman of Lundbeck’s Board of Directors. She brings a wealth of highly successful R&D and commercial experiences including a robust knowledge and experience in neuroscience. She is a proven and highly passionate leader and has all the qualifications to take Lundbeck to the next level as a global leader within psychiatric and neurological disorders.
Deborah Dunsire has lived in the U.S. since 1994, and grew up in South Africa where she graduated from University of the Witwatersrand, Johannesburg, in 1985. In connection with her new position, Deborah Dunsire plans to move to Denmark from the U.S.